Halozyme's royalty stream powers 39% quarterly revenue surge and a higher full-year forecast
Royalties of $341.0m made up most of Halozyme's $493.0m third-quarter revenue, and management now expects 2026 sales of $1.860bn to $1.925bn.
Royalties from partners' subcutaneous drugs are the main engine of Halozyme Therapeutics' business. In the quarter ended 30 September 2026 they accounted for $341.0m of $493.0m in total revenue, roughly seven dollars in every ten. The company reported the figures on 5 November and said revenue was up 39%.
Halozyme credited sales of three partner products that use its ENHANZE delivery technology: VYVGART Hytrulo, DARZALEX SC and Phesgo. After the quarter, it set a new 2026 revenue range of $1.860bn to $1.925bn. The company did not say in the material reviewed what the range replaces.
On the dealmaking side, Halozyme said it widened its ENHANZE agreements with argenx, Incyte and Janssen during the period. It also moved three programmes into Phase 1. Financial terms, the products covered and the identity of the programmes were not disclosed in the material reviewed.
Two other items came with the results. A Dutch court has granted an injunction against Merck's Keytruda Qlex over a patent Halozyme describes as relating to MDASE, and the company completed a $1.5bn convertible notes offering. The details of the ruling and of the financing, including pricing and use of proceeds, were not available.
Why it matters
- Halozyme's earnings lean heavily on royalties from drugs sold by others, so partner sales largely set its trajectory.
- The expanded agreements with argenx, Incyte and Janssen, plus three Phase 1 entrants, suggest the ENHANZE platform is still adding partner activity, though no terms were disclosed.
- The Dutch injunction against Keytruda Qlex puts a subcutaneous formulation of a major oncology drug at the centre of a patent dispute. Its scope and consequences are not yet clear from the available information.
Company's press release (SEC filing): Halozyme Therapeutics, Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
BeyondSpring wins FDA Fast Track for plinabulin-docetaxel in post-immunotherapy NSCLC as cash dwindles to $0.6M
Calidi cuts costs and restructures as Q3 loss reaches $3.6M ahead of CLD-401 IND
Beyond Air reports record $2.3M quarterly revenue as FDA reviews second-generation LungFit PH
DataMEDS AI Q3 revenue up 50% to $2.7M on GLP-1 dispensing
Curis reports Q3 loss of $8.1m as emavusertib trials enrol; cash runway reaches only early 2027
